High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia

被引:23
作者
Jeddi, Ramzi [1 ]
Ghedira, Hela [1 ]
Mnif, Samia [2 ]
Gouider, Emna [1 ]
Fenaux, Pierre [3 ]
Meddeb, Balkis [1 ]
机构
[1] Aziza Othmana Univ Hosp, Dept Hematol, Tunis 1008, Tunisia
[2] Inst Pasteur, Dept Hematol, Tunis, Tunisia
[3] Univ Paris 13, Avicenne Hosp, AP HP, Dept Hematol, Paris, France
关键词
Acute promyelocytic leukemia; Differentiation syndrome; Body mass index; Obesity; TRANS-RETINOIC ACID; MYELOID-LEUKEMIA; CHEMOTHERAPY; EXPRESSION; INDUCTION; THERAPY; PETHEMA; ALPHA; RISK;
D O I
10.1016/j.leukres.2009.09.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased BMI has been correlated to an increased incidence of APL, but not to the occurrence of differentiation syndrome (DS) in APL. We consecutively treated 39 APL patients with ATRA and idarubicin ( according to PETHEMA regimen). Median age was 26 years. Forty-one percent patients were classified as intermediate risk, and 59% as high risk according to Sanz's score. Thirty-three patients (85%) reached CR. Eleven of the 36 patients evaluable for DS (30.5%) developed this syndrome (severe in 7 cases, moderate in 4, and fatal in 3 cases) within a median of 12 days (range 3-23) of ATRA onset. Six of the 9 (66.6%) patients with BMI >= 30 developed DS vs. 5 of 27 (18.5%) with BMI<30 (p = 0.012). Other predictors of DS in univariate analysis were: age >= 40 year (p = 0.033), baseline WBC >= 20 x 10(9)/l (p = 0.003), and creatinine > 1.4 mg/dl (p = 0.009). In multivariate analysis, BMI >= 30 remained an independent predictor of DS in addition to baseline WBC >= 20 x 10(9)/l. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:545 / 547
页数:3
相关论文
共 14 条
[1]  
ATKINSON K, 1994, CLIN BONE MARROW TRA, P760
[2]   Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia [J].
De Botton, S ;
Dombret, H ;
Sanz, M ;
San Miguel, J ;
Caillot, D ;
Zittoun, R ;
Gardembas, M ;
Stamatoulas, A ;
Condé, E ;
Guerci, A ;
Gardin, C ;
Geiser, K ;
Makhoul, DC ;
Reman, O ;
de la Serna, J ;
Lefrere, F ;
Chomienne, C ;
Chastang, C ;
Degos, L ;
Fenaux, P .
BLOOD, 1998, 92 (08) :2712-2718
[3]   Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia [J].
Estey, E ;
Thall, P ;
Kantarjian, H ;
Pierce, S ;
Kornblau, S ;
Keating, M .
LEUKEMIA, 1997, 11 (10) :1661-1664
[4]   A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia [J].
Fenaux, P ;
Chastang, C ;
Chevret, S ;
Sanz, M ;
Dombret, H ;
Archimbaud, E ;
Fey, M ;
Rayon, C ;
Huguet, F ;
Sotto, JJ ;
Gardin, C ;
Makhoul, PC ;
Travade, P ;
Solary, E ;
Fegueux, N ;
Bordessoule, D ;
San Miguel, J ;
Link, H ;
Desablens, B ;
Stamatoullas, A ;
Deconinck, E ;
Maloisel, F ;
Castaigne, S ;
Preudhomme, C ;
Degos, L .
BLOOD, 1999, 94 (04) :1192-1200
[5]   THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA [J].
FRANKEL, SR ;
EARDLEY, A ;
LAUWERS, G ;
WEISS, M ;
WARRELL, RP .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (04) :292-296
[6]   Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia [J].
Jeddi, Ramzi ;
Kacem, Karima ;
Ben Neji, Hend ;
Mnif, Samia ;
Gouider, Emna ;
Aissaoui, Lamia ;
Ben Amor, Ramzi ;
Ben Lakhal, Raihane ;
Ben Abid, Hela ;
Belhadjali, Zaher ;
Meddeb, Balkis .
HEMATOLOGY, 2008, 13 (03) :142-146
[7]   Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptotic activities [J].
Konopleva, M ;
Mikhail, A ;
Estrov, Z ;
Zhao, SR ;
Harris, D ;
Sanchez-Williams, G ;
Kornblau, SM ;
Dong, J ;
Kliche, KO ;
Jiang, SW ;
Snodgrass, HR ;
Estey, EH ;
Andreeff, M .
BLOOD, 1999, 93 (05) :1668-1676
[8]   Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors [J].
Montesinos, Pau ;
Bergua, Juan M. ;
Vellenga, Edo ;
Rayon, Chelo ;
Parody, Ricardo ;
de la Serna, Javier ;
Leon, Angel ;
Esteve, Jordi ;
Milone, Gustavo ;
Deben, Guillermo ;
Rivas, Concha ;
Gonzalez, Marcos ;
Tormo, Mar ;
Diaz-Mediavilla, Joaquin ;
Gonzalez, Jose D. ;
Negri, Silvia ;
Amutio, Elena ;
Brunet, Salut ;
Lowenberg, Bob ;
Sanz, Miguel A. .
BLOOD, 2009, 113 (04) :775-783
[9]  
Sanz MA, 2000, BLOOD, V96, P1247
[10]   Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:: a multicenter study by the PETHEMA group [J].
Sanz, MA ;
Martín, G ;
González, M ;
León, A ;
Rayón, C ;
Rivas, C ;
Colomer, D ;
Amutio, E ;
Capote, FJ ;
Milone, GA ;
de la Serna, J ;
Román, J ;
Barragán, E ;
Bergua, J ;
Escoda, L ;
Parody, R ;
Negri, S ;
Calasanz, MJ ;
Bolufer, P .
BLOOD, 2004, 103 (04) :1237-1243